Janssen ProCast Brasil
Virologia 2: Highlights Webinar HIV e COVID-19 - Dr. Estevão Portela
Episode Notes
Neste episódio, o Infectologista Dr. Estevão Portela e o Gerente de Assuntos Médicos Vinicius Zillmer respondem as principais perguntas que surgiram durante o Webinar HIV e COVID-19, que ocorreu dia 09 de abril.
Referências:
Refs:
- Qun Li et al., 2020; Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
- The New York Times, How Bad Will the Coronavirus Outbreak Get? Here Are 6 Key Factors, by Knvul Sheikh, Derek Watkins, Jin Wu and Mika Gröndahl (Updated Feb. 28, 2020). Disponível em: <https://www.nytimes.com/interactive/2020/world/asia/china-coronavirus-contain.html?searchResultPosition=3>
- CDC 2007. Disponível em: <https://www.cdc.gov/flu/pandemic-resources/pdf/community_mitigation-sm.pdf>
- Ferguson N et al., 2020. Disponível em: <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>
- COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Disponível em: <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>
- Public Health Agency of Sweden. Disponível em: <https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/protect-yourself-and-others-from-spread-of-infection/>
- Siddiqi e Mehra et al., 2020
- Cao et al. NEJM 2020 - A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
- Shen et. Al JAMA 2020 - JAMA Preliminary Communication March 27, 2020 - Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- Wu et al. JAMA 2020 - April 10, 2020 - Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China
- Wang M et al. Cell Res. 2020 - Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
- Xu X chinaXiv:202003.00026v1 2020 - Why tocilizumab could be an effective treatment for severe COVID-19?
- Gautret P Int J Antimicrob Agents. 2020 - Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
- Molina JM, Médecine et Mal Infectieuses 2020 - Knowledge and practices of Parisian family physicians for the management of men who have sex with men in the era of HIV pre-exposure prophylaxis.
- Cai Q , Engineering 2020 - TEMPORARY REMOVAL: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- Dong L, Drug Discov Ther. 2020 - Discovering drugs to treat coronavirus disease 2019 (COVID-19).
- Baron SA. et al. Int J Antimicrob Agents. 2020 - Teicoplanin: an alternative drug for the treatment of COVID-19?
- Elfiky A Life Sci. 2020 - Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
- Protocolo de Manejo de la Infección por SARS-CoV2 (COVID-19), versión 11. Disponível em: <https://portalarquivos.saude.gov.br/images/pdf/2020/April/14/Protocolo-de-Manejo-Cl--nico-para-o-Covid-19.pdf>
- Zhu F, Cao Y, Xu S, Zhou M. J Med Virol. 2020 Mar 11 - Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
- Guo W, Ming F, Dong Y, et al The Lancet - A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China
- COVID-19 in patients with HIV: clinical case series
- Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). Disponível em: <https://clinicaltrials.gov/ct2/show/NCT04303507>
- Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). Disponível em: <https://clinicaltrials.gov/ct2/show/NCT04318444>
- Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial. Disponível em: <https://clinicaltrials.gov/ct2/show/NCT04308668>
- Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study). Disponível em:<https://clinicaltrials.gov/ct2/show/NCT04304053>